MSM and Substances Cohort at UCLA Linking Infections Noting Effects (MASCULINE)

项目摘要/摘要 艾滋病毒的治疗和预防方法正在随着药物疗法的进步而不断发展。还没有 在美国，使用主要人群成员的物质，如与男性发生性关系的有色人种男性 (MoCSM)面临社会行为障碍，这些障碍阻碍了整个艾滋病毒护理和预防部门的获取和遵守 产生与艾滋病毒相关的生物变化的级联反应。阐明物质使用如何影响基础， 艾滋病毒的生物、行为和社会方面对推进艾滋病毒的预防和治疗至关重要。作为回应 至NIDA RFA-DA-18-011艾滋病毒/艾滋病与药物使用的队列研究(U01)，加州大学洛杉矶分校 洛杉矶(UCLA)寻求在UCLA继续MSM和物质队列，将感染联系在一起，注意到影响 (男性或“mSTUDY”)成立于2013年，旨在扩大它为另一个人提供的科学机会 五年了。我们提议的竞争性更新将维持和动态更新物质使用队列 HIV血清阳性(HIV+)和高危HIV血清阴性(HIV-)MoCSM通过退休的老年非物质使用 会员和增加年轻的物质使用者。如果续签，这个队列将继续增加我们的样本 具有良好特性的、广泛的生物行为库，并为高影响力的科学提供一个平台。 药物使用继续影响对治疗和预防方案的遵守，从而维持高水平 流行网络。拟议的研究人员领导着研究吸毒与吸毒之间的联系的科学 行为和传染病，并将为免疫学的广泛跨学科工作做出贡献 和基础科学到流行病学、预防和治疗。这批MoCSM将表现为：(I)效果 感染艾滋病毒和其他性传播感染(性传播感染：淋病、衣原体、 梅毒)；(2)与以下相比，MoCSM中的物质使用在多大程度上促进了传播艾滋病毒的行为 非药物使用MoCSM(Iii)物质使用和HIV对粘膜环境的影响；(Iv) 物质使用对艾滋病毒疾病进展的影响；以及物质使用与艾滋病毒感染之间的相互作用 炎症反应。我们确定兴奋剂、大麻和其他物质在 与特定行为相结合可以在多个方面改变HIV的传播和进展动力学 通过免疫功能和微生物群形成隔间。该应用程序还建议扩展已经存在的 强大的生物资料库，标本可供更广泛的研究社区使用。这批人将包括 重复数据访问的514个MoCSM。至少一半的人将是活跃的物质使用者，年龄在30岁以下。 有了一个完全登记的队列，mSTUDY已经开始出版影响很大的出版物和副产品研究 具有大样本量新集成数据集的项目。下一轮周期将进一步刺激基本面和 来自合作研究人员的生物创新科学，与其他NIDA新建立的合作 一批科学家，以及外部资助的科学家，并产生对未来科学的高度影响。

PROJECT SUMMARY/ABSTRACT HIV treatment and prevention approaches are evolving in response to advancements in pharmacotherapies. Yet in the United States substance using members of key populations such as men of color who have sex with men (MoCSM) face socio-behavioral barriers that inhibit access and adherence across the HIV Care and Prevention Cascades that produce HIV relevant biological changes. Elucidation of how substance use affects basic, biological, behavioral, and social aspects of HIV is vital to advance HIV prevention and treatment. In response to NIDA RFA-DA-18-011 Cohort Studies of HIV/AIDS and Substance Use (U01), the University of California, Los Angeles (UCLA) seeks to continue the MSM and Substances Cohort at UCLA Linking Infections Noting Effects (MASCULINE or the “mSTUDY”) established in 2013 and to extend the scientific opportunities it offers for another five years. Our proposed competitive renewal will sustain and dynamically refresh the cohort of substance-using HIV-seropositive (HIV+) and high-risk HIV-seronegative (HIV-) MoCSM by retiring older, non-substance-using members and adding younger substance-users. If renewed, this cohort will continue to add specimens to our well-characterized, extensive biobehavioral repository and to provide a platform for high-impact science. Substance use continues to effect adherence to treatment and prevention regimens thereby sustaining high prevalence networks. Proposed investigators lead the science on studying associations between drug use, behaviors, and infectious disease and will contribute a broad portfolio of interdisciplinary work from immunology and basic science to epidemiology, prevention and treatment. This cohort of MoCSM will characterize: (i) effects of substance use on acquisition of HIV and other sexually transmitted infections (STIs: gonorrhea, Chlamydia, syphilis); (ii) the extent to which substance use in MoCSM facilitates behaviors that transmit HIV compared to non-drug using MoCSM (iii) the effects of substance use and HIV on the mucosal environment; (iv) effect of substance use on HIV disease progression; and interactions between substance use and HIV infection on the inflammatory response. We identify the direct ways stimulants, cannabis and other substance use in combination with specific behaviors can change HIV transmission and progression dynamics in multiple compartments via immune function and the microbiome. The application also proposes to expand an already robust biorepository with specimens available for the broader research community. This cohort will be comprised of 514 MoCSM with repeated data visits. At least half will be active substance users and younger than age 30. With a fully enrolled cohort, the mSTUDY has begun to produce high impact publications and spinoff research projects with newly integrated datasets of large sample sizes. The next cycle will further stimulate basic and biologically innovative science from collaborating investigators, newly established collaborations with other NIDA cohorts, and externally funded scientists and generate high impact future science.